^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MEDI-3617

    i
    Other names: MEDI-3617
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    Angiopoietin 2 inhibitor, TIE inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. (PubMed, J Immunother Cancer)
    Tremelimumab in combination with MEDI3617 is safe in patients with advanced melanoma. Angiopoietin-2 inhibition in combination with immune checkpoint inhibition warrants further exploration.
    Clinical • P1 data • Journal
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • ICOS (Inducible T Cell Costimulator) • IL10 (Interleukin 10)
    |
    Imjudo (tremelimumab) • MEDI-3617